A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Phase 1/2 Recruiting 98 enrolled Sichuan Baili Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.

Timeline

Start: 2024-04-24
Primary completion: 2026-04
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BL-M07D1	Unknown	—	Intravenous

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Summary

Timeline

Drugs

Indications